Flutafarm Femina 125mg 30 tablets — Made in Ukraine — Free Delivery

Pharmacological properties

Pharmacodynamics. Flutapharm femina is a non-steroidal preparation with antiandrogenic action.

In women with hyperandrogenic conditions, accompanied by infertility and disorders of the ovarian-menstrual cycle (for example, scleropolycystic ovary syndrome), Flutapharm Femina blocks the pathogenic effect of endogenous androgens on the ovaries and other reproductive organs, as well as on the hypothalamic-pituitary system. Due to this, the severity of symptoms of hyperandrogenism (hirsutism) in patients decreases, menstruation resumes, folliculogenesis and menstrual cycle improve, which probably leads to the restoration of fertile potential in some patients.

Pharmacokinetics. Flutamide is well absorbed in the gastrointestinal tract. Cmax in the blood is observed 2 hours after oral administration. It is rapidly metabolized to form the active metabolite of 2-hydroxyflutamide and other substances. T½ of the active metabolite is 5-6 hours. It is eliminated mainly in the urine. In 2 days, 91% of the administered dose is excreted from the body, in 3 days - 98% of the administered dose.

Indications

Treatment of women with functional hyperandrogenism, which is accompanied by disorders of the ovarian-menstrual cycle, hirsutism, scleropolycystic ovary syndrome and infertility.

Application

For women with hyperandrogenic conditions, flutapharm femina should be administered orally 1 tablet (125 mg) 3 times a day for 3–6 months. take with or after meals. it is mandatory to use non-hormonal contraceptives, in particular, barrier ones.

Children. The preparation should not be used to treat children.

Contraindications

Hypersensitivity to flutamide or other components of the preparation. hyperandrogenism of organic origin (tumors of the ovaries and adrenal cortex). severe hepatic impairment (baseline liver enzymes should be assessed before starting treatment).

Side effects

The following adverse reactions were observed with the use of the preparation  in men.

With monotherapy

Reproductive system: gynecomastia and / or breast pain, sometimes accompanied by galactorrhea. These reactions disappear after stopping treatment or reducing the dose of the preparation. The incidence of gynecomastia is significantly reduced with concomitant use of LHRH agonists. Decreased libido, decreased sperm count.

Infections and invasions: herpes zoster.

Blood and lymphatic system: edema, ecchymosis, lymphostasis.

Immune system: lupus-like syndrome.

Mental disorders: depression, anxiety, embarrassment, anxiety.

Nervous system: insomnia, headache, dizziness.

Organ of vision: blurred vision.

Respiratory system: dyspnea, cough.

Digestive tract: diarrhea, nausea, vomiting, increased appetite, gastrointestinal dysfunction, pain in the stomach, ulcerative pain, heartburn, constipation, anorexia, thirst.

Hepatobiliary system: increased activity of liver enzymes, transient liver dysfunction, jaundice, hepatitis.

Skin and subcutaneous tissue: itching, rash.

General disorders: increased fatigue, malaise, weakness, fever, chest pain.

Violations of the cardiovascular system occur much less frequently compared with the use of diethylstilbestrol.

Special instructions

Patients should be under constant medical supervision. special attention should be paid to the effect of the preparationon liver function.

Treatment with the preparation should not be started if the levels of hepatic transaminases in the blood plasma are 2-3 times higher than the upper limit of the norm. Monitoring of liver function should be carried out during the entire period of preparation treatment. Plasma transaminase levels should be determined before starting flutamide therapy, monthly during the first 4 months of taking the preparation ,periodically thereafter and at the first symptoms of liver dysfunction (for example, itching, dark urine, nausea, vomiting, fatigue, anorexia, jaundice, pain in right hypochondrium or incomprehensible flu-like symptoms). If jaundice appears or the activity of hepatic transaminases is 2-3 times higher than normal (in the absence of liver metastases, confirmed by biopsy), flutamide should be stopped immediately and liver function should be carefully monitored until the situation is clarified.

Patients should see a doctor immediately when the first symptoms of liver dysfunction appear, such as pruritus, dark urine, nausea, vomiting, persistent anorexia, yellowing of the sclera and skin, tenderness in the right hypochondrium, and flu-like symptoms.

Liver damage is usually reversible after discontinuation of therapy, and in some patients even after dose reduction.

Flutamide is excreted mainly by the kidneys; therefore, dose adjustment may be required in patients with renal insufficiency.

Since plasma levels of testosterone and estradiol increase during treatment with flutamide, fluid retention in body tissues is possible. Therefore, flutamide should be used with caution in patients with heart disease. In addition, an increase in estradiol levels may increase the risk of thromboembolism.

Patients with latent or actual glucose-6-phosphate deficiency may develop methemoglobinemia. In the event of cyanosis, methemoglobinemia, the possible factor of excess dose should be taken into account.

Flutamide contains lactose, therefore, patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should not use the preparation.

Before using Flutapharm Femina, women need to exclude organic hyperandrogenism (tumors of the ovaries and adrenal cortex).

Alcohol should not be consumed during treatment.

Use during pregnancy and lactation. When using the preparation, women should pay special attention to preventing pregnancy with the help of non-hormonal, in particular barrier, contraceptives. In case of a positive pregnancy test, the preparation should be stopped immediately. Sexual intercourse with the aim of the desired pregnancy can be resumed no earlier than 48 hours after the last dose of Flutapharm Femina.

The ability to influence the reaction rate when driving or working with other mechanisms. Until the individual patient's response to the preparation is clarified, one should refrain from driving vehicles or other mechanisms, given that during treatment with flutamide, increased fatigue, sometimes dizziness, drowsiness and visual disturbances were observed.

Interactions

In patients receiving warfarin for a long time, after the start of monotherapy with flutamide, there is an increase in prothrombin time. therefore, with the combined use of flutapharm femin and warfarin, careful control of prothrombin time and, possibly, correction of anticoagulant doses are necessary.

Flutamide can slow down the metabolism of GCS.

Avoid the combined use of flutamide with potentially hepatotoxic preparations.

When flutamide is used simultaneously with theophylline, an increase in the concentration of theophylline in blood plasma is possible.

Excessive alcohol consumption should be avoided during treatment with flutamide.

Overdose

A single dose of flutamide that would cause overdose symptoms or be life-threatening has not been established.

In case of overdose, dialysis is ineffective, given the high degree of binding of flutamide to blood plasma proteins.

As with the treatment of an overdose of any preparation, the possibility of taking several preparations at the same time should be considered. In case of overdose, if there is no spontaneous vomiting, vomiting should be induced. Gastric lavage may be required.

Shown are standard supportive measures with constant monitoring of the patient and vital functions.

Storage conditions

In its original packaging at a temperature not exceeding 25 ° c.